Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other financing activities (2018)

Denali Therapeutics (DNLI) has disclosed Other financing activities for 1 consecutive years, with -$1.3 million as the latest value for Q4 2018.

  • On a quarterly basis, Other financing activities changed N/A to -$1.3 million in Q4 2018 year-over-year; TTM through Sep 2019 was -$1.3 million, a 196.72% decrease, with the full-year FY2018 number at $44000.0, changed N/A from a year prior.
  • Other financing activities was -$1.3 million for Q4 2018 at Denali Therapeutics, down from $1.3 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.3 million in Q1 2018 to a low of -$1.3 million in Q2 2018.